Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...

Up until now, patients in Horsham and Crawley could just turn up at Horsham and Crawley hospitals for on-the-spot tests. But ...

Hastings Public Schools Foundation, Mary Lanning Healthcare Foundation, and Central Community College have all agreed to ...

Student accommodation is being lined up for a new GP surgery in the county. Applicant Dr Khunti has put forward plans to ...